Funded Tech Companies
Convergent Therapeutics
Convergent Therapeutics, operating out of Cambridge, received equity investments through OrbiMed, Invus and RA Capital Management.
Company Overview
Company Name
Convergent Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Undisclosed
Cambridge, MA Undisclosed
USA
Cambridge, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
5/3/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philip Kantoff
Chief Operating Officer
Alex Brown
Chief Scientific Officer
Neil Bander
Company Investors
- OrbiMed (Tal Zaks)
- Invus
- RA Capital Management (Jake Simson)
Browse more funded tech companies:
Convergent Media Systems | ConvergeOne
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs